Analysts' Top 5 Price Targets of April 7, 2025

Axsome Therapeutics [US05464T1043]: Jefferies starts coverage with a Buy rating and a price target of $200 (112% upside potential) The biotechnology company currently markets three drugs for the central nervous system, with two more expected to follow in 2025 and 2026. Auvelity, a drug for the treatment of depression, could achieve peak sales of $1.5-2 billion on its own. The expected revenue for the entire Axsome pipeline for 2025 is only $620 million. This makes the rest of the pipeline a "call option," according to Jefferies. The experts are...